Skip to results
Modify your search
NARROW
1-20 of 38
Authors: Filip Van den Bosch
Journal Article
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies
Rheumatology, keaf009, https://doi.org/10.1093/rheumatology/keaf009
Published: 11 January 2025
Journal Article
Prevalence and incidence of uveitis in patients with spondyloarthritis: the impact of the biologics era. Data from the international ASAS-COMOSPA study Get access
Rheumatology, Volume 64, Issue 5, May 2025, Pages 2618–2624, https://doi.org/10.1093/rheumatology/keae536
Published: 03 October 2024
Journal Article
P167 Bimekizumab achieved sustained improvements in efficacy outcomes in patients with axial spondyloarthritis, regardless of prior tumour necrosis factor inhibitor treatment: week 52 pooled results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2
Rheumatology, Volume 63, Issue Supplement_1, April 2024, keae163.206, https://doi.org/10.1093/rheumatology/keae163.206
Published: 24 April 2024
Journal Article
E089 Effect of secukinumab on radiographic progression and inflammation in sacroiliac joints and spine in patients with non-radiographic axial spondyloarthritis: 2-year imaging outcomes from a Phase III randomised trial
Rheumatology, Volume 62, Issue Supplement_2, April 2023, kead104.338, https://doi.org/10.1093/rheumatology/kead104.338
Published: 24 April 2023
Journal Article
P185 Long-term efficacy and safety of upadacitinib in patients with psoriatic arthritis refractory to biologic therapies: 2-year results from the phase 3 SELECT-PsA 2 study
Rheumatology, Volume 62, Issue Supplement_2, April 2023, kead104.226, https://doi.org/10.1093/rheumatology/kead104.226
Published: 24 April 2023
Journal Article
Ultrasound-guided core needle biopsy and incisional biopsy of the parotid gland are comparable in diagnosis of primary Sjögren’s syndrome
Rheumatology, Volume 62, Issue 8, August 2023, Pages 2765–2772, https://doi.org/10.1093/rheumatology/keac714
Published: 27 December 2022
Journal Article
EDITOR'S CHOICE
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2122–2129, https://doi.org/10.1093/rheumatology/keac605
Published: 25 October 2022
Journal Article
Performance of an MRI scoring system for inflammation of joints and entheses in peripheral SpA: post-hoc analysis of the CRESPA trial
Rheumatology, Volume 62, Issue 6, June 2023, Pages 2130–2138, https://doi.org/10.1093/rheumatology/keac567
Published: 06 October 2022
Journal Article
Work participation is unaffected in Belgian spondyloarthritis patients: data from the BelGian Inflammatory Arthritis and SpoNdylitis cohorT
Rheumatology, Volume 62, Issue 5, May 2023, Pages 1841–1850, https://doi.org/10.1093/rheumatology/keac529
Published: 13 September 2022
Journal Article
Anti-CD74 IgA antibodies show diagnostic potential for axial spondyloarthritis but are not associated with microscopic gut inflammation
Rheumatology, Volume 62, Issue 2, February 2023, Pages 984–990, https://doi.org/10.1093/rheumatology/keac384
Published: 04 July 2022
Journal Article
Cluster analysis in early axial spondyloarthritis predicts poor outcome in the presence of peripheral articular manifestations
Rheumatology, Volume 61, Issue 8, August 2022, Pages 3289–3298, https://doi.org/10.1093/rheumatology/keab873
Published: 03 December 2021
Journal Article
Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis
Rheumatology, Volume 61, Issue 8, August 2022, Pages 3279–3288, https://doi.org/10.1093/rheumatology/keab887
Published: 30 November 2021
Journal Article
IL-23 and axial disease: do they come together?
Rheumatology, Volume 60, Issue Supplement_4, October 2021, Pages iv28–iv33, https://doi.org/10.1093/rheumatology/keab617
Published: 20 October 2021
Journal Article
Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis
Rheumatology, Volume 61, Issue 5, May 2022, Pages 2054–2062, https://doi.org/10.1093/rheumatology/keab653
Published: 17 September 2021
Journal Article
P194 Response to ixekizumab by C-reactive protein level in patients with aadiographic axial spondyloarthritis: results from the COAST-V (biological-naïve) and COAST-W (TNF-α inhibitor-experienced) trials at 52 weeks
Rheumatology, Volume 60, Issue Supplement_1, April 2021, keab247.189, https://doi.org/10.1093/rheumatology/keab247.189
Published: 26 April 2021
Journal Article
P171 Efficacy and safety of upadacitinib in patients with active PsA and inadequate response to biologic DMARDs (SELECT-PsA-2): a double-blind, randomised controlled Phase III trial
Rheumatology, Volume 60, Issue Supplement_1, April 2021, keab247.166, https://doi.org/10.1093/rheumatology/keab247.166
Published: 26 April 2021
Journal Article
The burden of psoriatic arthritis in the biologics era: data from the Belgian Epidemiological Psoriatic Arthritis Study
Rheumatology, Volume 60, Issue 12, December 2021, Pages 5677–5685, https://doi.org/10.1093/rheumatology/keab233
Published: 12 March 2021
Journal Article
TNFi-induced sustained clinical remission in peripheral spondyloarthritis patients cannot be maintained with a step-down strategy based on methotrexate
Rheumatology, Volume 60, Issue 10, October 2021, Pages 4880–4883, https://doi.org/10.1093/rheumatology/keab056
Published: 20 January 2021
Journal Article
EP38 Secukinumab provides sustained improvement of enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal Phase 3 studies
Rheumatology, Volume 59, Issue Supplement_2, April 2020, keaa109.037, https://doi.org/10.1093/rheumatology/keaa109.037
Published: 20 April 2020
Journal Article
P219 Long-term safety of filgotinib in patients with PsA: week 52 safety data from a Phase 2 open-label extension study
Rheumatology, Volume 59, Issue Supplement_2, April 2020, keaa111.214, https://doi.org/10.1093/rheumatology/keaa111.214
Published: 20 April 2020
